STAAR SURGICAL CO
STAANASDAQTrading Snapshot
- Day Range
- $22.09 โ $22.49
- 52-Week Range
- $15.59 โ $35.87
- Volume
- $2.93B
- Avg Volume
- $3.03B
- Shares Outstanding
- 49.8M
- Next Earnings
- Dec 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $239M
- Last Q Revenue
- $94M
- P/E Ratio
- 256.4
- P/S Ratio
- 3.0x
- EPS (TTM)
- $0.08
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +4.0%
Why Investors Own STAA
- โHigh-growth profile โ revenue up +50.6% YoY with expanding US Equity exposure.
- โHealthy economics โ 43% gross margin and 25% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
STAAR SURGICAL CO
STAAAbout STAAR SURGICAL CO
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Analyst Price Target
โLatest News & Updates

This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Here Are Tuesdayโs Top Wall Street Analyst Research Calls: AutoZone, Baker Hughes, FS KKR Capital, Kroger, Netflix, PepsiCo, Ryder Systems, SpaceX, Warner Bros. Discovery, and More
Markets opened Tuesday on edge as surging oil prices, climbing Treasury yields, and a rejected Iran ceasefire rattled traders heading into the final stretch of Q3. Find out which major names on Wall Street got upgraded,

Contrasting Sensus Healthcare (NASDAQ:SRTS) and STAAR Surgical (NASDAQ:STAA)
Sensus Healthcare (NASDAQ: SRTS - Get Free Report) and STAAR Surgical (NASDAQ: STAA - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based o

Why Staar Surgical Stock Soared Today
It anticipates this will run for one year. The company's recent fundamentals have been rather impressive.

STAAR Surgical Board Approves $50 Million Share Repurchase Authorization
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVOโข family of Implantable Collamerยฎ Lenses (EVO ICLโข) for vision correction, today announced that it

Is Staar Surgical Co (STAA) a Bargain After 4.1% Drop? GF Value Says Undervalued
On September 23, 2026, Staar Surgical Co (STAA) shares fell by 4.1%, closing at $19.80. The stock has had a turbulent year, trading within a 52-week range of $1